Business Overview

  • Therapeutic drugs

  • Clinical nutrition

  • Diagnostics

  • Medical devices

Revenue¥955.2 billion*
Business profit¥197.2 billion

*Revenue includes intersegment revenue and transfers

Otsuka focuses on the fields of psychiatry, neurology and oncology as priority areas under the theme of addressing unmet medical needs. In addition, by working in a wide range of other fields and businesses including the cardiovascular and renal system, digestive system, ophthalmology, diagnostics, intravenous solutions and medical devices, we provide comprehensive healthcare services from diagnosis to treatment.

Initiatives in the Pharmaceutical Business

Psychiatry and Neurology

Aiming to become a top-class global player in the psychiatry and neurology area, with a high-potential pipeline and product portfolio

Psychiatric diseases such as schizophrenia, bipolar disorder, and major depressive disorder can develop at any age and affect a person's social life, career, and studies. Moreover, concerns are growing about the increasing frequency of Alzheimer's-related dementia as populations worldwide continue to age. These diseases affect not just the patient's quality of life; they also place a strain on family members and caregivers, as well as on the healthcare economy. There are still many psychiatric and neurological diseases for which satisfactory treatments have yet to be established. This is because their causes and mechanisms are not fully understood, which makes the discovery of new drugs extremely difficult. The Otsuka group entered the psychiatry and neurology area in the 1970s and has continued to take on the challenge of new drug discovery with the goal of contributing to medical needs.
We have a high-potential pipeline and product lineup, and aim to become a top-class global player in this area.


Maximizing business value by combining group strengths

Taiho Pharmaceutical engages in drug discovery, leveraging its long-standing proprietary platform focused on biochemical modulation, as well as drug discovery based on its research platform, such as the newly established Cysteinomix and kinase target drug discovery. Furthermore, through its collaboration with relation to Astex Pharmaceuticals' fragment-based drug discovery technology, Taiho Pharmaceutical continues to discover new molecular targeting drugs.
Meanwhile, centering on external collaborations, Otsuka Pharmaceutical is taking on the challenge of establishing therapies with a focus on the future. This includes creating synergies with new modalities, in areas such as gene-modified T cell therapies and oncolytic virus therapies.
Individual group companies are combining their drug discovery technologies and assets to bolster global operations and enhance business value.

Cardiovascular and Renal System

Creating first-in-class products through new drug discovery technologies, and medical devices

In the cardiovascular and renal area, in addition to strengthening our proprietary drug discovery platforms, we also plan to actively make growth investments, examples of which have included our business alliance with Akebia Therapeutics for vadadustat, and the acquisition of Visterra, a company with a renal disease-related pipeline. We also strive to find solutions to unmet needs in non-pharmaceutical areas too. We are advancing development of unique medical devices, drawing on our innovative technology and our strengths in drugs and clinical research. Examples include a device for ultrasound renal denervation treatment and a peripheral artery stent system. We aim to create first-in-class products leveraging these new drug discovery technologies and medical devices.

R&D Pipeline

An overview of the Otsuka group's R&D pipeline.

R&D Pipeline

Major R&D Sites

The Otsuka group has built a network of R&D sites worldwide, developing a global structure for the research and development of innovative new products to aid in the treatment of diseases and support day-to-day health.

  • Tokushima Research Institute (10th Research Center),
    Otsuka Pharmaceutical
  • Tokushima Research Institute (Hi-z Tower), Otsuka Pharmaceutical

Group Company R&D Websites